Cao Yifeng, Ma Yifeng, Tao Yi, Lin Weifeng, Wang Ping
College of Pharmaceutical Science, Zhejiang University of Technology, Hangzhou 310014, China.
Department of Molecular Chemistry and Materials Science, Weizmann Institute of Science, Rehovot 76100, Israel.
Pharmaceutics. 2021 Dec 15;13(12):2166. doi: 10.3390/pharmaceutics13122166.
Osteoarthritis (OA) is the most prevalent degenerative joint disease affecting millions of people worldwide. Currently, clinical nonsurgical treatments of OA are only limited to pain relief, anti-inflammation, and viscosupplementation. Developing disease-modifying OA drugs (DMOADs) is highly demanded for the efficient treatment of OA. As OA is a local disease, intra-articular (IA) injection directly delivers drugs to synovial joints, resulting in high-concentration drugs in the joint and reduced side effects, accompanied with traditional oral or topical administrations. However, the injected drugs are rapidly cleaved. By properly designing the drug delivery systems, prolonged retention time and targeting could be obtained. In this review, we summarize the drugs investigated for OA treatment and recent advances in the IA drug delivery systems, including micro- and nano-particles, liposomes, and hydrogels, hoping to provide some information for designing the IA injected formulations.
骨关节炎（OA）是最常见的退行性关节疾病，影响着全球数百万人。目前，OA的临床非手术治疗仅限于缓解疼痛、抗炎和关节腔注射补充透明质酸。开发改善病情的骨关节炎药物（DMOADs）对于OA的有效治疗至关重要。由于OA是一种局部疾病，关节内（IA）注射可将药物直接输送到滑膜关节，使关节内药物浓度升高且副作用减少，同时结合传统的口服或局部给药方式。然而，注射的药物会迅速被分解。通过合理设计药物递送系统，可以延长药物保留时间并实现靶向性。在本综述中，我们总结了用于OA治疗的研究药物以及IA药物递送系统的最新进展，包括微米和纳米颗粒、脂质体和水凝胶，希望为设计IA注射制剂提供一些信息。
